Mary Thistle - 08 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)

Role
Director
Signature
/s/ Mary Thistle
Issuer symbol
AKTS
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
3
Filing time
08 Jan 2026, 20:57:47 UTC
Previous filing
27 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thistle Mary Director C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON /s/ Mary Thistle 08 Jan 2026 0001317917

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 74,913 $10.66 Direct F1
holding AKTS Stock Option (Right to Buy) 08 Jan 2026 Common Stock 18,933 $18.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the original number of shares subject to the option shall vest on January 15, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
F2 The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

Exhibit 24 - Power of Attorney